In this online, self-learning activity:
Migraine headache is the leading condition of recurrent cephalalgias of moderate or severe intensity. The condition has been identified as one of the most common neurological disorders occurring in adult women (17%) approximately three times more than in men: in the U.S. 17.1% of women and 5.6% of men experience at least one migraine per year. It is one of the top five reasons for emergency department visits by patients ages 18 to 44.
A provider’s first priority when seeing a patient with headaches is to determine whether the patient is presenting with a primary headache disorder or a secondary headache disorder. Primary headache disorders include migraine headaches, tension-type headaches, and cluster headaches. Secondary headaches are those attributed to an underlying condition such as infection, trauma, vascular disorders, or structural lesions. They cost thousands of per patient per year and are the third leading cause of disability in the world.
Recent Advances in Therapeutics Now Informing
Mechanism of Disease
Recent Advances in Therapeutics Now Informing
Mechanism of Disease
Healthcare professionals who are: primary care physicians, neurologists, headache specialists, nurse practitioners, physician assistants, nurses, and pharmacists who specialize in neurology and primary care; and those who otherwise commonly care for or clinically encounter patients who may experience migraine headache.
This program is supported by an educational grant from AMGEN.
This activity is free of charge.
Release Date: May 31, 2019 -- Expiration Date: May 31, 2021
Faculty: Joshua Kamins, MD
Primer and updates on the epidemiology, pathophysiology, clinical presentation, and diagnosis of migraine headaches
|
Updates in the treatment of patients with migraine headaches
|
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure:
Joshua Kamins, MD, professor at UCLA, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care
Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies